Immunosuppressant will undergo multi-center clinical trials in the U.S. and Europe starting "within a few months," the company says. FK506, discovered in the fermentation broth of Streptomyces tsukubaensis, inhibits the production of interleukin-2 and the expression of IL-2 receptors. Animal models indicate FK506 may be useful for rheumatoid arthritis, Behcet's diseases of the eyes and psoriasis. Investigator meetings were slated for March 5-6 in London and March 8-9 in Bethesda.
You may also be interested in...
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
US FDA Commissioner Race Shrinks And Widens: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as FDA Commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.